$110.08
0.93% day before yesterday
Nasdaq, May 30, 10:12 pm CET
ISIN
US3755581036
Symbol
GILD
Sector
Industry

Gilead Sciences Stock price

$110.08
+3.54 3.32% 1M
+16.06 17.08% 6M
+17.71 19.17% YTD
+46.00 71.79% 1Y
+45.28 69.88% 3Y
+34.92 46.46% 5Y
-4.00 3.51% 10Y
Nasdaq, Closing price Fri, May 30 2025
-1.03 0.93%
ISIN
US3755581036
Symbol
GILD
Sector
Industry

Key metrics

Market capitalization $136.93b
Enterprise Value $153.96b
P/E (TTM) P/E ratio 23.27
EV/FCF (TTM) EV/FCF 16.02
EV/Sales (TTM) EV/Sales 5.36
P/S ratio (TTM) P/S ratio 4.77
P/B ratio (TTM) P/B ratio 7.15
Dividend yield 2.80%
Last dividend (FY24) $3.08
Revenue growth (TTM) Revenue growth 4.68%
Revenue (TTM) Revenue $28.74b
EBIT (operating result TTM) EBIT $10.97b
Free Cash Flow (TTM) Free Cash Flow $9.61b
Cash position $7.93b
EPS (TTM) EPS $4.73
P/E forward 18.10
P/S forward 4.78
EV/Sales forward 5.37
Short interest 1.99%
Show more

Create a Free Account to create an Gilead Sciences alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Gilead Sciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

30 Analysts have issued a Gilead Sciences forecast:

18x Buy
60%
12x Hold
40%

Analyst Opinions

30 Analysts have issued a Gilead Sciences forecast:

Buy
60%
Hold
40%

Financial data from Gilead Sciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
28,735 28,735
5% 5%
100%
- Direct Costs 6,239 6,239
1% 1%
22%
22,496 22,496
6% 6%
78%
- Selling and Administrative Expenses 5,857 5,857
6% 6%
20%
- Research and Development Expense 5,671 5,671
0% 0%
20%
15,126 15,126
18% 18%
53%
- Depreciation and Amortization 4,157 4,157
52% 52%
14%
EBIT (Operating Income) EBIT 10,969 10,969
8% 8%
38%
Net Profit 5,965 5,965
1,132% 1,132%
21%

In millions USD.

Don't miss a Thing! We will send you all news about Gilead Sciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Gilead Sciences Stock News

Positive
Seeking Alpha
about 20 hours ago
We explain why selling cash-covered puts and covered calls is a relatively safe choice for earning high income. We will discuss how to formulate a sustainable and repeatable income strategy for options. This monthly series identifies stocks suitable for writing options to generate consistent income, emphasizing a 10-15% annual return.
Positive
Reuters
about 20 hours ago
Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, according to results of a large trial presented on Saturday.
Neutral
Business Wire
about 20 hours ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) reduced the risk of disease progression or death by 35% (HR: 0.65) versus standard of care Keytruda plus chemotherapy in first-line treatment for patients with PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer (TNBC). Trodelvy w...
More Gilead Sciences News

Company Profile

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.

Head office United States
CEO Daniel O'Day
Employees 17,600
Founded 1987
Website www.gilead.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today